This week the US Food and Drug Administration approved the release of fingolimod (trade name Gilenya®), the first oral medication for the treatment of remitting relapsing multiple sclerosis. Swedish Neuroscience Institute is proud to have participated in the pivotal clinical trial that led to the approval of Gilenya. Gilenya is a welcome addition to the set of medications available to patients living with MS. There are currently five injectable therapies and two intravenous therapies approved by the FDA for the treatment of MS. Although these treatments are very effective, many patients have been hoping for an oral alternative. Some patients are finding that they have “injection fatigue” or are running out of places to inject the medication. It is important to note, however, that not all patients should switch to Gilenya. Patients with stable disease should remain on their medications. Patients need to be informed of the risks associated with Gilenya, including slowed heart rate, increased blood pressure, difficulty breathing, abnormal liver function, and infection, and how these risks may apply to them. If you are wondering whether Gilenya is right for you, please ask your neurologist.
Recommended for you
Swedish is one of only a few U.S. centers involved in trials designed to prove the safety of a new artificial disc for degenerative disc disease patients.
Virtual visits bring advanced care to more communities and relieve the strain and cost of traveling for many patients with MS.
Essential tremor ran in this family. Swedish neuroscience experts used focused ultrasound to treat the condition, which has plagued them for decades. Learn more.
Providence Swedish experts share some advice for building supportive relationships between patients, caregivers and loved ones.
Tofersen, a new drug, is the first gene therapy for a familial form of amyotrophic lateral sclerosis.
A Swedish expert discusses the autoimmune disease and its diagnosis and treatment.
A Swedish behavioral health expert offers guidance for finding our way back to center when life feels overwhelming.
Seattle’s KING 5 TV hosted a panel of sought-after Swedish specialists for a conversation about advanced treatments at Swedish and why patients from around the world choose us for their care.
A Swedish patient shares his experience of the procedure's life-changing success.
A Swedish expert explains aphasia, a disorder that affects the area of your brain that controls language and communication.
Occupational Therapist Simon Gale, the program's leader, on New Day Northwest. Share the thrill of skydiving with a program participant.
The Parkinson’s Foundation Comprehensive Care Center designation recognizes leadership in providing high-quality care for patients with Parkinson’s disease.
Nancy Isenberg, M.D., medical director of Swedish’s Center for Healthy Aging, weighs in.
Providence Swedish joined a host of community partners on June 21 for a Brain Health Block Party to raise awareness about the importance of brain health.
The American Heart Association presents the Get With The Guidelines awards for proven dedication to best practices and life-saving care.
Clinical research at The Ivy Center at Swedish offers advanced, personalized care for brain tumors. Learn what’s giving our experts new hope.
Stroke: Symptoms, risk and other tips from a Swedish expert
The community event brought together Swedish experts and local artists who shared best practices for aging well physically, emotionally and mentally.
Swedish is home to a Certified Center of Excellence for ALS care and offers patients the highest levels of multi-disciplinary care.
A movement expert at Swedish shares how research, medication and teamwork is improving care for people with Parkinson’s disease.